Neovasc Inc (US) (NVCN) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) from a hold rating to a sell rating in a report published on Thursday.

According to Zacks, “Neovasc Inc. is a specialty medical device company. It develops, manufactures and markets products for the cardiovascular marketplace. The Company’s products include the Tiara (TM) mitral valve prosthesis in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer (TM) for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products, including transcatheter heart valves. Neovasc Inc. is headquartered in Richmond, Canada. “

How to Become a New Pot Stock Millionaire

Several other equities research analysts have also weighed in on NVCN. ValuEngine lowered Neovasc Inc (US) from a sell rating to a strong sell rating in a research report on Sunday, December 31st. Canaccord Genuity restated a buy rating and set a $1.05 price target on shares of Neovasc Inc (US) in a research report on Friday, January 19th. Finally, Leerink Swann dropped their target price on Neovasc Inc (US) from $5.00 to $2.00 and set an outperform rating on the stock in a report on Thursday, March 29th.

NASDAQ NVCN opened at $0.06 on Thursday. The company has a debt-to-equity ratio of -0.89, a quick ratio of 0.75 and a current ratio of 0.77. Neovasc Inc has a twelve month low of $0.03 and a twelve month high of $1.89. The company has a market cap of $29.17, a P/E ratio of -0.17 and a beta of 1.20.

An institutional investor recently raised its position in Neovasc Inc (US) stock. Gagnon Advisors LLC grew its stake in Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) by 50.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,829,482 shares of the medical equipment provider’s stock after acquiring an additional 610,376 shares during the quarter. Neovasc Inc (US) accounts for 0.8% of Gagnon Advisors LLC’s portfolio, making the stock its 28th biggest holding. Gagnon Advisors LLC owned about 2.32% of Neovasc Inc (US) worth $1,098,000 as of its most recent filing with the Securities and Exchange Commission. 41.47% of the stock is owned by institutional investors.

WARNING: This story was published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3342370/neovasc-inc-us-nvcn-stock-rating-lowered-by-zacks-investment-research.html.

Neovasc Inc (US) Company Profile

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

Get a free copy of the Zacks research report on Neovasc Inc (US) (NVCN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

James River Group  Upgraded to Hold by BidaskClub
James River Group Upgraded to Hold by BidaskClub
MGM Growth Properties  Stock Rating Upgraded by Zacks Investment Research
MGM Growth Properties Stock Rating Upgraded by Zacks Investment Research
PulteGroup  Upgraded to “Buy” by B. Riley
PulteGroup Upgraded to “Buy” by B. Riley
Nexeo Solutions  Lowered to “Hold” at Zacks Investment Research
Nexeo Solutions Lowered to “Hold” at Zacks Investment Research
The Walt Disney  Upgraded to “Market Perform” by BMO Capital Markets
The Walt Disney Upgraded to “Market Perform” by BMO Capital Markets
STMicroelectronics  Posts  Earnings Results, Beats Estimates By $0.01 EPS
STMicroelectronics Posts Earnings Results, Beats Estimates By $0.01 EPS


© 2006-2018 Ticker Report. Google+.